Small molecule biotechnology company Iambic Therapeutics (IAM.US) IPO priced at $15-17 per share, aiming to raise $150 millions.

According to Golden Ten Data APP, Iambic Therapeutics (IAM.US), a clinical-stage biotechnology company based in San Diego, California that develops small molecule anti-cancer therapies using its proprietary artificial intelligence (AI) platform, announced its IPO terms on Thursday. The company plans to raise $150 million by offering 9.4 million shares at a price range of $15 to $17 per share. Some investors have indicated interest in subscribing for $60 million worth of shares in this offering (accounting for 40% of the transaction). Based on the midpoint of the proposed price range, Iambic Therapeutics’ fully diluted market capitalization would reach $809 million.

Iambic Therapeutics is a clinical-stage biotechnology company that combines proprietary AI models with automated high-throughput chemistry and biology to design small molecule drugs. The platform operates a closed-loop process: its models propose compound candidates, the robotic lab synthesizes and tests hundreds of compounds for each project weekly, and the resulting data is used to retrain the models. Its main drug candidate, IAM1363, is a selective, blood-brain barrier-penetrant HER2 inhibitor, currently undergoing Phase 1/1b clinical trials for HER2-altered solid tumors, with registrational trials potentially beginning as early as 2027; two other preclinical projects targeting KIF18A and CDK2/4 are planned to submit IND applications in the fourth quarter. To date, Iambic Therapeutics has generated revenue through collaborations with companies such as AbbVie (ABBV.US), Takeda Pharmaceuticals (TAK.US), and Bayer (BAYRY.US).

Iambic Therapeutics was founded in 2019 and achieved $18 million in revenue over the 12 months ending June 30, 2026. The company plans to list on Nasdaq under the ticker IAM. JPMorgan, Jefferies, BofA Securities, and Citi are serving as joint bookrunners for this offering. Pricing is expected during the week of October 12, 2026.